CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults.

Meghann Wheeler; Julie W. Merten; Benjamin T Gordon; Hanadi Hamadi

doi:10.1080/10826084.2020.1729201

CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults.

Meghann Wheeler, Julie W. Merten, Benjamin T Gordon, Hanadi Hamadi

University of North Florida

Research output: Contribution to journal › Article › peer-review

Abstract

Cannabidiol (CBD), a non-psychoactive component of cannabis is marketed as a potential treatment for many conditions and widely available to purchase as a dietary supplement. In 2017, sales of CBD exceeded 820 million dollars despite many unconfirmed health claims, murky legality, and limited product efficacy and safety testing.

Original language	American English
Journal	Substance Use & Misuse
Volume	55
DOIs	https://doi.org/10.1080/10826084.2020.1729201
State	Published - Feb 24 2020

Disciplines

Medicine and Health Sciences
Public Health
Family Medicine

Access to Document

10.1080/10826084.2020.1729201License: Unspecified

Cite this

@article{e21bd14f518c4fa59c22a5dff031f506,

title = "CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults.",

abstract = "Cannabidiol (CBD), a non-psychoactive component of cannabis is marketed as a potential treatment for many conditions and widely available to purchase as a dietary supplement. In 2017, sales of CBD exceeded 820 million dollars despite many unconfirmed health claims, murky legality, and limited product efficacy and safety testing.",

author = "Meghann Wheeler and Merten, {Julie W.} and Gordon, {Benjamin T} and Hanadi Hamadi",

year = "2020",

month = feb,

day = "24",

doi = "10.1080/10826084.2020.1729201",

language = "American English",

volume = "55",

journal = "Substance Use & Misuse",

issn = "1082-6084",

}

TY - JOUR

T1 - CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults.

AU - Wheeler, Meghann

AU - Merten, Julie W.

AU - Gordon, Benjamin T

AU - Hamadi, Hanadi

PY - 2020/2/24

Y1 - 2020/2/24

N2 - Cannabidiol (CBD), a non-psychoactive component of cannabis is marketed as a potential treatment for many conditions and widely available to purchase as a dietary supplement. In 2017, sales of CBD exceeded 820 million dollars despite many unconfirmed health claims, murky legality, and limited product efficacy and safety testing.

AB - Cannabidiol (CBD), a non-psychoactive component of cannabis is marketed as a potential treatment for many conditions and widely available to purchase as a dietary supplement. In 2017, sales of CBD exceeded 820 million dollars despite many unconfirmed health claims, murky legality, and limited product efficacy and safety testing.

UR - https://doi.org/10.1080/10826084.2020.1729201

U2 - 10.1080/10826084.2020.1729201

DO - 10.1080/10826084.2020.1729201

M3 - Article

SN - 1082-6084

VL - 55

JO - Substance Use & Misuse

JF - Substance Use & Misuse

ER -

CBD (Cannabidiol) Product Attitudes, Knowledge, and Use Among Young Adults.

Abstract

Disciplines

Access to Document

Other files and links

Cite this